News

A team of researchers at the University of Pennsylvania and the University of Florida have identified a pulmonary hypertension treatment using a drug grown in the leaves of plants from Penn’s high-tech greenhouse. This potential mode of therapy, addressing a disease for which few therapy options exist,…

Scientists continue to research the various environmental and lifestyle risk factors associated with PAH. Now, new research is revealing additional clues into how a person’s own genetics can predispose them to developing the disease. A recent review entitled “Genetics of pulmonary hypertension” published in November issue…

A new study entitled “mTORC1 Is Involved in Hypoxia-Induced Pulmonary Hypertension Through the Activation of Notch3” published in Journal of Cellular Physiology reports that both mTORC1 and Notch3 signaling pathways are associated with Hypoxia-Induced Pulmonary Hypertension. In hypoxic pulmonary hypertension (HPH), one of the…

Quebec residents living with pulmonary arterial hypertension (PAH) now have access to a breakthrough, publicly funded drug called Opsumit (macitentan), a once-a-day oral formulation of a dual endothelia receptor antagonist (ERA). On October 1, the Institut national d’excellence en santé et services sociaux (INESSS) recommended that the Régie de l’assurance maladie…

New research is shedding light on the progression of CTEPH. A novel study on chronic thromboembolic pulmonary hypertension (CTEPH), entitled “Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients” published in the European Respiratory Journal  by Dr. Diana Zabini, part…

A protein within the glycolytic metabolism pathway, which is key to providing energy for cell processes, is increased in induced animal models of pulmonary arterial hypertension. This finding, reported in the journal Respiratory Research in an article entitled, “Up-regulation of Hexokinase 1 in…

Chloe Temtchine, a singer who suffers from pulmonary hypertension and decided to advocate for the disease using her career, is performing at the New York City O2 breathe Gala on November 6, 2014. Temtchine is going to sing her theme Be Brave, which was launched last…

When admitted to the intensive care unit (ICU), chances are high that the patient has an existing condition in addition to the affliction causing their admittance to the ICU. It is vital that these existing conditions be considered by clinicians when developing a course of treatment, as many times…

A recent study, entitled “The use of antidepressants and the risk of idiopathic pulmonary arterial hypertension,” which is set to be published in The Canadian Journal of Cardiology by Dr. Benjamin D. Fox, of the Centre for Clinical Epidemiology, Jewish General Hospital, and collaborators, addresses the…

A new study entitled “Improved survival of Korean patients with idiopathic pulmonary arterial hypertension after the introduction of targeted therapies” published in August issue of the Heart & Lung journal reports targeted therapies for treatment of idiopathic pulmonary arterial hypertension (IPAH) significantly improve IPAH patients’ survival. IPAH is a serious condition characterized by increased blood pressure in pulmonary arteries, frequently culminating in heart failure. Despite several approved treatments, IPAH currently has no cure, and treatments tend to treat symptoms of the disease rather than the underlying cause. Previously, IPAH conventional treatments included oxygen supplementation to fight the lack of oxygen due to pulmonary vaso constriction, anticoagulants to prevent vascular thrombosis associated with IPAH, as well as digoxin and diuretics. However, data concerning survival rates among IPAH patients who are prescribed these treatments are lacking in…

One of the fundamental steps to gaining more support for much-needed research and development is to first raise awareness among the general public and potential investors. One of the most effective means of rallying support is to publish inspiring stories about people living with a…

The Maryland-based Pulmonary Hypertension Association (PHA), the most prominent organization in the country committed to the prevention, research, education, and advocacy of pulmonary hypertension (PH), has just announced that it has accredited the first 6 Pulmonary Hypertension Care Centers (PHCC) in the US, as part of its…